The current recommendation is to stop semaglutide at least 2 months before planned pregnancy and tirzepatide at least 1 month before
Gastrointestinal adverse events were reported in 62% of the group taking semaglutide, compared to 42% in the placebo group.[ref] Bigger picture of GLP-1 in the rise of obesity: Several recent studies shed light on how environmental factors may be causing a decrease in GLP-1 levels
Finding the right medical team Managing Hashimoto's on GLP-1 therapy requires coordinated medical care
Yu H, Rimbert A, Palmer AE, Toyohara T, Xia Y, Xia F, Ferreira LMR, Chen Z, Chen T, Loaiza N
and Geneocopy Inc
Before tirzepatide, Lilly was developing its own GLP-1-only agonists (e.g., dulaglutide) and amylin analogs, and it launched baricitinib/therapies in inflammation